A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

NCT02047565 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Bleeding

Interventions

DRUG: 60mg edoxaban
DRUG: 180mg edoxaban
DRUG: 50 IU/kg Beriplex P/N
DRUG: 25 IU/kg Beriplex P/N
DRUG: 10 IU/kg Beriplex P/N

Sponsor

Daiichi Sankyo